300 related articles for article (PubMed ID: 25253666)
41. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
42. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
43. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
[TBL] [Abstract][Full Text] [Related]
44. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
[TBL] [Abstract][Full Text] [Related]
45. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
46. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Wood N; Marshall H; White OJ; Holt PG; McIntyre P
Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
[TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
48. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
Cherry JD; Gornbein J; Heininger U; Stehr K
Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
50. Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis.
Abu-Raya B; Maertens K; Munoz FM; Zimmermann P; Curtis N; Halperin SA; Rots N; Barug D; Holder B; Rice TF; Kampmann B; Leuridan E; Sadarangani M
Vaccine; 2021 Oct; 39(44):6545-6552. PubMed ID: 34598822
[TBL] [Abstract][Full Text] [Related]
51. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
Lavigne MV; Castro M; Andino J; Manghi M
Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
[TBL] [Abstract][Full Text] [Related]
52. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.
Esposito S; Agliardi T; Giammanco A; Faldella G; Cascio A; Bosis S; Friscia O; Clerici M; Principi N
Infect Immun; 2001 Jul; 69(7):4516-20. PubMed ID: 11401994
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
Kang KR; Huh DH; Kim JA; Kang JH
BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
[TBL] [Abstract][Full Text] [Related]
54. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
57. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
58. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
[TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
[TBL] [Abstract][Full Text] [Related]
60. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
Ryan M; Gothefors L; Storsaeter J; Mills KH
Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
